Shanghai Kehua Bio-Engineering Co., Ltd. Class A
SSZSE:0020225.43
CNY
0.00
(0.00%)
ISIN
CNE000001KC9
Return %
Stock
S&P 500
1Y
-18.83
13.14
3Y
-33.62
80.78
5Y
-60.13
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Li Ming
- Full Time Employees
- 1,870
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Caohejing Hi-Tech Park Shanghai SH China 200233
- IPO Date
- Jul 5, 2004
- Website
- skhb.com
- Similar Companies
- Business
- Shanghai Kehua Bio-Engineering Co., Ltd. (002022.SZ) develops, manufactures, and markets a comprehensive portfolio of in vitro diagnostic (IVD) products, including reagents and instruments for immunodiagnostics, clinical chemistry, molecular diagnostics, mass spectrometry, and point-of-care testing (POCT). The company offers over 260 NMPA-registered products and more than 80 CE-certified reagents and instruments, alongside automated analyzers such as the Polaris series chemiluminescence immunoassay systems and innovative solutions like the Tianlong Panall 8000 all-in-one molecular diagnosis system; it also provides diagnostic laboratory instruments, evacuated receptacles, and specialized kits including Helicobacter pylori antibody detection reagents and AIDS diagnostics prequalified by WHO. Products serve hospitals, disease control centers, blood banks, biopharmaceutical firms, and research institutions, with exports to over 100 countries via partnerships with domestic and international agents. Founded in 1981 and headquartered in Shanghai, China, the company maintains R&D centers and production bases in Italy, Shenzhen, Xi'an, Suzhou, and other locations, employing nearly 2,000 staff plus 1,000 at subsidiary Tianlong Technology; it operates 33 subsidiaries including Xi'an Tianlong Science & Technology, Guangzhou Focus Diagnostics, and Italy's Technogenetics S.P.A. (TGS). Geographically, operations span China across 30+ provinces and extend globally, with a focus on integrated reagent-instrument solutions driven by dual R&D platforms. In recent developments, Shanghai Kehua signed an investment cooperation agreement in April 2025 with the Xi'an Economic and Technological Development Zone Management Committee for a medical devices and testing reagents production base plus medical industry incubation center spanning 90 acres in two phases, enhancing chemiluminescence and reagent manufacturing capacity. Subsidiaries secured multiple regulatory approvals in 2024-2025, including NMPA certificates for Helicobacter pylori kits (December 2024) and fully automated chemiluminescence analyzers from Shaanxi authorities (April 2024), alongside Tianlong products gaining further medical device registrations. The company deepened global collaborations through joint exhibitions at MEDICA 2024, ADLM 2024, CACLP 2025, and Medlab 2025 with subsidiaries Tianlong and TGS, yielding exclusive distribution deals such as for the Biolum ATP hygiene system in Egypt; additionally, Xi'an Zhitong Benyi Enterprise Management Partnership agreed to acquire a 5% stake from Zhuhai Baolian.